Developmental Malformations
Vein of Galen malformations
Sep. 22, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Reducing body myopathy
- Updated 02.26.2024
- Released 11.21.1996
- Expires For CME 02.26.2027
Reducing body myopathy
Introduction
Overview
Reducing body myopathy, a rare condition with early infant to adult onset, is characterized by abnormal inclusions in muscle fibers that are highlighted by special stains. A protein, FHL1, has been identified in these inclusions by proteomic techniques, and mutations in the corresponding gene have been identified in both sporadic and familial cases. Although the pathophysiology remains poorly understood, inclusions may be involved in processing and assembling ribosomes. Thus, their activity seems to be intimately related to muscle mass and function and leads to progressive muscle weakness, with wasting and, in some, death due to respiratory failure.
Key points
|
• Reducing body myopathy is rare and manifests as infant/early childhood and adult-onset forms. | |
|
• The disorder may be chronic and benign, or progressive and fatal. | |
|
• Presentation can involve muscles of the upper or lower body, which may be affected in symmetric or asymmetric fashion. | |
|
• Cytoplasmic inclusions identified microscopically may represent processing defects of ribosomes. | |
|
• Cases may be sporadic; familial cases appear to be X-linked recessive (developing from mutations in FHL1) or autosomal dominant with variable penetrance. | |
|
• Death is most often from respiratory failure, although cardiomyopathies may contribute. |
Historical note and terminology
Reducing body myopathy is a rare disease of skeletal muscle, often classified as a congenital myopathy, although onset is more likely in early infancy (12) and adult onset is recognized. This condition was first described in two unrelated children in whom muscle biopsy showed unusual structures that were termed "reducing bodies" (05). Over 30 cases have been reported in the medical literature, and the clinical presentation is variable.
Muscle biopsies show variation in muscle fiber size; fibers may be regenerative, necrotic, or swirled, with the latter showing desmin and dysferlin accumulation (21). Reducing bodies are defined by distinctive histochemical and ultrastructural abnormalities. Histologically, reducing bodies contain a substance that can reduce dihydroxydinaphthyl disulfide, confirming that sulfhydryl groups are present. They also stain black with menadione-linked alpha-glycerophosphate dehydrogenase and are able to reduce nitroblue tetrazolium even in the absence of the substrate alpha-glycerophosphate, giving the same intensive stain. By electron microscopy, reducing bodies appear as dense osmiophilic material that, at higher magnification, consists of closely packed variably and irregularly shaped particles mixed with fibrillar material, measuring 12 nm to 18 nm in width. Proliferation of cytoplasmic bodies and rimmed vacuoles is recognized. In reducing body myopathy, cytoplasmic bodies (CBs) may localize to peripheral, subsarcolemmal regions, giving an appearance termed “necklace cytoplasmic bodies” (53).
Clinical manifestations
Presentation and course
According to age at onset, reducing body myopathy may be classified into three forms: (1) a severe infantile form in which the disease starts during the first 4 years of life with rapid progression and fatal outcome due to respiratory failure (05; 12; 06; 26); (2) congenital, with delayed developmental milestones and relatively benign course mimicking nemaline rod myopathy and central core disease (52; 37); and (3) late-onset form with a progressive course (22; 36; 04; 35). Eight patients with the severe infantile type (12; 06; 26) or with the late-onset form (22; 04; 14) showed asymmetric limb weakness and wasting at onset, with a progressive course advancing to severe generalized muscle wasting, weakness, and respiratory failure. Slight to moderate elevation of creatine kinase has been reported in a subset of patients. Peripheral neuropathy has not been reported. Both dilated and hypertrophic forms of cardiomyopathy are recognized, and inclusions are identified in some samples of cardiac muscle (47). Female carriers of the X-linked form may have mild muscle weakness proximally or be asymptomatic, which may represent varying degrees of X-inactivation (44; 08). Presentation and muscle involvement are variable and may be asymmetric, involving upper or lower muscle groups (15). Preservation or hypertrophy of gluteus maximus in the context of lower leg muscle wasting has been advanced as a diagnostic clue (25). Axial muscle involvement can be pronounced, with fatty infiltration of postero-medial thigh muscles identified by MRI (21).
Prognosis and complications
The cases reported as congenital variants of reducing body myopathy have a benign course and static muscle weakness. Severe infantile variants and late-onset variants, frequently starting with asymmetric limb weakness, show progressive muscle weakness with loss of motor functions, swallowing difficulty, and respiratory failure. Scoliosis, spinal rigidity, and contractures (especially involving the Achilles tendon) may also develop (46; 45). At the mild end of the FHL1 spectrum, myopathic changes can be weak, with only isolated ankle contractures (39). In a case of adult onset, progression was slow (ie, several years), although it resulted in diffuse weakness (14). The presence of a cardiomyopathy, most often of the dilated type (although the hypertrophic form may also occur), complicates the clinical course.
Clinical vignette
A patient, the fifth of seven siblings, was admitted at the age of 15 years for progressive generalized weakness. The parents were not related, and the mother had two spontaneous abortions. Pregnancy and delivery were uneventful. The patient had normal intellectual and motor development. Muscle weakness appeared at 9 years when she started to fall frequently, had difficulty standing up from sitting, and had a waddling gait with left leg lag. At that time neurologic examination disclosed generalized weakness in a proximal distribution. Creatine kinase was slightly elevated (110 UI; normal value < 70). At 10 years, she had severe lordosis, winging of the scapulae, and bilateral pes equinus. By 13 years of age, she was restricted to a wheelchair. Neurologic examination showed an alert girl with normal intellectual function. There was a generalized severe muscle weakness with limitation of elbow and knee joints. Neck movements also were limited but bulbar functions and facial movements were spared. Respiratory function test showed a restrictive respiratory syndrome. Cardiological examinations were normal. Laboratory rheumatological tests, creatine kinase, and lactate dehydrogenase were normal. EMG of the right quadriceps muscle showed a myopathic pattern with few fibrillation potentials and no spontaneous discharges. Motor and sensory nerve conduction studies were normal.
A muscle biopsy was performed on the right triceps brachii. Morphology of the muscle biopsy showed marked endomysial fibrosis and increased diameter variability. Most fibers contained round or polymorphic masses that stained dark purple with modified Gomori trichrome and were closely related to smaller multiple round or oval, bright red cytoplasmic bodies.
Many of these fibers also contained rimmed vacuoles. These polymorphic masses stained dark brown with menadione-nitroblue tetrazolium reaction and did not stain for oxidative enzymes, myofibrillar ATPase, or myophosphorylase.
Reducing bodies showed negative immunofluorescence with antibodies for keratins and vimentin and positive immunofluorescence with antibodies for desmin, and were closely related with some round bright red rod-shaped structures when using phalloidin-rhodamine.
Ultrastructurally, these bodies showed two types of myofibrillar abnormalities: (1) some areas composed of finely granular and filamentous material resembling cytoplasmic bodies; and (2) strongly osmiophilic large masses composed at high magnification of tubular-filamentous profiles of 16 to 17 nm in diameter resembling reducing bodies. Biochemical studies confirmed an increased amount of proteins at 53 kd (desmin) and 70 kd (not characterized further). These bodies are composed of FHL1 protein (33).
Biological basis
Etiology and pathogenesis
Until 2008, the cause of reducing body myopathy was unknown. Various etiologies had been considered, including a viral infection, an RNA disorder, and a myofibrillar degeneration disorder. New proteomic technology is proving helpful in understanding the composition of these inclusions (32). When the cellular inclusions characteristic of the myopathy were dissected using laser technology followed by chromatography-tandem mass spectrometry and proteomic analysis, the protein FHL1 (four-and-half-LIM protein 1) was identified (47). At least 10 mutations have been identified in 15 patients from 10 families (46; 48). Additional mutations in FHL1 continue to be identified (49), with whole exome sequencing diagnostic in the mildest forms (39). Experimental and clinical evidence suggests that the myopathy results from a loss of FHL1 function (11; 54). The sporadic appearances in females, absence of male-to-male transmission, and familial appearances in severely affected sons and less affected mothers strongly support an X-linked pattern of inheritance.
Other myopathies associated with FHL1 mutations include X-linked myopathy with postural muscle atrophy and scapuloperoneal myopathy (54). Although clinical features vary among these disorders, each manifests similar protein aggregates in muscle. Cardiomyopathies of the dilated or hypertrophic form also occur in patients with FHL1 mutations (10).
Brooke and Neville first suggested a viral or ribosomal origin, but these causes were excluded later by others because these bodies did not exhibit orange-red fluorescence after staining with acridine orange (05). The condition is not transmissible in rat muscle or in primate kidney cultures (06; 26). However, transfection of cultured kidney and skeletal muscle cells with mutant FHL1 causes the formation of inclusions (47). FHL1 localizes to the sarcomere and is involved in muscle growth and differentiation. As a consequence, deletions are associated with muscle hypertrophy (28; 55) and strength enhancement (09). Mutations in the FHL1 gene or other genes in the FHL family have been identified in other myopathies (56). In addition to its effect on skeletal muscle, the FHL1 gene plays a role in certain cardiomyopathies, probably through several pathways (56; 08). The type or location of gene mutations (at least 11 are recognized) are thought to be important in genotype-phenotype relationships (44; 08) and continue to be elucidated. For example, reducing body myopathy has been associated with filamin C mutations in a child born to first cousins (24).
In patients with reducing body myopathy, many muscle fibers show bizarre and abnormal nuclei (06) or degenerating nuclei (26), myofiber necrosis, and phagocytosis. Reducing bodies are particularly abundant in fibers undergoing degeneration of myofibrils and nuclei. Many of these fibers also show increased rimmed vacuole formation, suggesting active autophagic phenomena. These bodies are strongly positive for ubiquitin, whose synthesis increases in various neuromuscular disorders with proliferation of rimmed vacuoles and abnormally increased filamentous proteins such as inclusion-body myositis (01), oculopharyngeal dystrophy (29), and distal myopathy with rimmed vacuole formation (43). Continuing research supports the involvement of an aggresome-autophagy pathway in FHL1-associated pathophysiology (42). In one study, strong immunoreactivity to dystrophin, alpha-sarcoglycan, and vimentin was reported (14). By electron microscopy, reducing bodies are composed of characteristic tubulo-filamentous structures of 12 to 18 nm in diameter closely related with intermediate filaments and thin filaments (04; 14). Using TUNEL staining, Ikezoe and colleagues have demonstrated significant increases in the density of DNA fragments in myonuclei and intensity of chromatin condensation, suggesting that apoptosis plays a role in muscle fiber degeneration (23). Because reducing bodies contain material that appears to be preribosomes and associated proteins and stain positively for nucleolar organizer regions, they resemble nucleoli and may result from defects in the processing and assembly of ribosomes (50) or impaired extralysosomal degradation of proteins (19). Misfolded proteins appear to accumulate in the endoplasmic reticulum and are, in this way, important to the formation of reducing bodies (30).
The few biochemical studies have shown an increase of a 53-kd protein (06) by 1-dimensional SDS-polyacrylamide gel electrophoresis corresponding to desmin by Western blot studies (04). Other proteins of 62 kd and 70 kd, characterized only by gel electrophoresis, are also abnormally elevated (06; 04). Increased desmin was proved also by immunofluorescence in three cases (04; 35; 14) but has not been confirmed by others (26). Two-dimensional electrophoresis demonstrates that desmin hyperphosphorylated isoforms are increased. This is analogous to what is found in other neuromuscular disorders characterized by a biochemical increase in desmin but with different clinical and ultrastructural features (41). For these reasons, the remarkable increase of desmin may be involved in the pathogenesis of the disease but appears to be a secondary phenomenon. Precursors to reducing bodies and other inclusions (fingerprint bodies, cylindrical spirals, zebra bodies, hyaline bodies, and tubular aggregates) have not been identified (17; 18).
Epidemiology
The disorder is extremely rare in the childhood group of myopathies. Over 30 cases have been reported in the medical literature. Reducing body myopathy also seems to be a rare morphological abnormality because only three biopsies showed such abnormalities in a review of 3500 muscle biopsies (26).
Prevention
To date, nine affected families have been recognized, but some are without molecular confirmation (45). None of the parents were consanguineous. In a family with a large kinship of seven sibs, there were two spontaneous abortions (04). Because of the extreme rarity of the condition, the gene frequency is presently unknown and genetic screening at the population level highly impractical. Reichmann and colleagues reported a father and daughter with progressive proximal myopathy and rigid spine phenotype (40). In the father, anatomic changes consisted of cytoplasmic bodies, increased desmin, sarcoplasmic and intranuclear tubulo-filamentous inclusions, and features of reducing body myopathy. The possibility of autosomal dominant inheritance was suggested by these cases. A second family, reported by Goebel and colleagues, also had changes suggestive of a mixed congenital myopathy in the maternal grandmother, mother, and teenaged male proband (20). The young man began having symptoms at 5 years of age (progressive rigid spine, torsion scoliosis, and flexion contractures of the elbows, hips, knees, and ankles); biopsies at 7, 11, and 14 years of age showed reducing bodies and cytoplasmic bodies ultrastructurally. Grandmother developed weakness in the hands and legs after 50 years; histologic examination showed similar inclusions, though they were not further characterized by histochemistry or electron microscopy. Mother’s muscle biopsy showed increased fiber diameters in quadriceps. The authors concluded that if the condition(s) was/were familial, genetic transmission would most likely have been X-linked recessive, though autosomal dominant transmission with variable penetrance was also possible. In another family, the mother developed foot-drop at 29 years and was confined to a wheelchair by 34; her son began having difficulty dressing at 10 years of age and could not stand alone a year later (38). Both autosomal dominant and X-linked recessive inheritance have been postulated (40; 17; 38).
Differential diagnosis
Associated or underlying disorders
For the congenital-onset form, reducing body myopathy has to be distinguished from all the disorders that cause floppiness in infancy. Severe infantile and late-onset forms may give the impression of an inflammatory myopathy if muscle weakness progresses quickly or may be confused with a facioscapulohumeral dystrophy when there is asymmetrical wasting and weakness. This disorder must be differentiated from other myopathies that show proliferation of cytoplasmic bodies, particularly cytoplasmic body myopathy (03) or other disorders with increased immunochemistry for desmin (41). Morphology of the muscle biopsy in reducing body myopathy is distinctive if combined with histochemical and ultrastructural findings. Reducing body-like inclusions have been observed in late-onset glycogen storage disease type II (16), scapuloperoneal myopathy, and rigid spine syndrome (08). FHL1 mutations cause a number of heterogeneous myopathies in addition to reducing body myopathy; these include X-linked scapulo-axio-peroneal myopathy (scapuloperoneal myopathy), rigid spine syndrome, and X-linked myopathy with postural muscle atrophy. Patients with hypertrophic cardiomyopathy or Emery-Dreifuss muscular dystrophy may show less expression of the gene (54; 13). Myopathies related to FHL1 mutations may or may not have reducing bodies (07). Reducing body myopathy was diagnosed in a 6-year-old patient with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy, suggesting the co-occurrence of an immune-mediated mechanism and highlighting the need for systematic workups (51).
Diagnostic workup
With the discovery of FHL1 involvement in patients with reducing body myopathy and other previously uncharacterized myopathies, mutation screening takes on obvious importance in diagnosis (56). The diversity of clinical and pathologic findings emphasizes this importance and the need for genotype-phenotype correlation (31). Patients and families should be worked up fully by obtaining complete histories, including family details and neurologic examination; a serum creatine kinase should be performed because it may be slightly elevated. Electromyography shows a myopathic pattern, and nerve conduction studies exclude peripheral neuropathy. In one study, MRI showed a distinctive pattern of involvement of posterior and medial muscles of the thigh and soleus in the lower leg, with sparing of (hypertrophic) gluteal muscles (02). In a CT-based study, imaging showed early changes in the flexors of thigh and brachium and, later, more severe degeneration of paraspinal musculature (27). Mohassel and colleagues also described the ultrasound and MRI characteristics of reducing body myopathy (34). Muscle ultrasound revealed elevated echointensity in skeletal muscles, specifically affecting deeper fascicles in areas like the biceps and tibialis anterior. Lower limb MRI indicated selective sparing of certain muscles like the gluteus maximus, rectus femoris, gracilis, and lateral gastrocnemius, displaying an asymmetric, multifocal, and "geographical" T1 hyperintensity pattern within the affected muscles. Muscle changes should be characterized by muscle biopsy and studied with histochemistry, including menadione-nitroblue tetrazolium stain, avoiding the substrate for alpha-glycerophosphate dehydrogenase. These methods will demonstrate round and polymorphic masses in many fibers that stain dark purple with the modified Gomori trichrome associated with typical cytoplasmic bodies. Frequently, type 1 fiber predominance with myofibrillar ATPase stain and proliferation of rimmed vacuoles are noted. These bodies are highly acidophilic in hematoxylin and eosin, are negative for oxidative enzyme activity, and show reducing activity. Electron microscopy shows typical osmiophilic masses composed of granular or tubulo-filamentous profiles mixed with autophagic vacuoles, cytoplasmic bodies, and accumulation of glycogen and intermediate filaments. Immunofluorescence for desmin and ubiquitin will show an increased signal in correspondence to reducing bodies in most cases. Biochemical studies by 1- and 2-dimensional electrophoresis should be performed to confirm the increase of other proteins in addition to desmin (06; 04).
Management
The patient should be advised to lead as normal a lifestyle as possible. Physical therapy becomes important when the progression of the disease causes remarkable motor weakness and disability in addition to scapular winging, joint contractures, and rigid spine with kyphoscoliosis.
Patients should be monitored periodically for nocturnal respiratory oxygen desaturation and with respiratory function tests when respiratory failure is present.
Special considerations
Pregnancy
Affected women have given birth, but in most instances this appears to have occurred before onset of symptoms.
Anesthesia
Limitations are applicable as for all myopathies with respiratory failure. Malignant hyperthermia has not been reported in reducing body myopathy. Anesthetics should be given with caution, as is generally advised with any myopathy.
Media
References
- 01
- Askanas V, Serdaroglu P, Engel WK, Alvarez RB. Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy. Neurosci Lett 1991;130:73-6. PMID 1660975
- 02
- Astrea G, Schessl J, Clement E, et al. Muscle MRI in FHL1-linked reducing body myopathy. Neuromuscular Disord 2009;19(10):689-91. PMID 19616434
- 03
- Bertini E, Ricci E, Boldrini R, et al. Involvement of respiratory muscles in cytoplasmic body myopathy--a pathological study. Brain Dev 1990;12(6):798-806. PMID 2092592
- 04
- Bertini E, Salviati G, Apollo F, et al. Reducing body myopathy and desmin storage in skeletal muscle: morphological and biochemical findings. Acta Neuropathol (Berl) 1994;87:106-12. PMID 8140891
- 05
- Brooke MH, Neville HE. Reducing body myopathy. Neurology 1972;22:829-40. PMID 4117299
- 06
- Carpenter S, Karpati G, Holland P. New observations in reducing body myopathy. Neurology 1985;35(6):818-27. PMID 4000482
- 07
- Chen T, Lu X, Shi Q, et al. FHL1-related myopathy may not be classified by reducing bodies in muscle biopsy. Neuromuscul Disord 2020;30(2):165-72. PMID 32001145
- 08
- Cowling BS, Cottle DL, Wilding BR, D'Arcy CE, Mitchell CA, McGrath MJ. Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: a comprehensive review of the clinical, histological and pathological features. Neuromuscul Disord 2011;21(4):237-51. PMID 21310615
- 09
- Cowling BS, McGrath MJ, Nguyen MA, et al. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J Cell Biol 2008;183(6):1033-48. PMID 19075112
- 10
- D’Arcy C, Kanellakis V, Forbes R, et al. X-linked recessive distal myopathy with hypertrophic cardiomyopathy caused by a novel mutation in the FHL1 gene. J Child Neurol 2015;30(9):1211-7. PMID 25246303
- 11
- Domenighetti AA, Chu PH, Wu T, et al. Loss of FHL1 induces an age-dependent skeletal muscle myopathy associated with myofibrillar and intermyofibrillar disorganization in mice. Hum Mol Genet 2014;23(1):209-25. PMID 23975679
- 12
- Dubowitz V. Muscle disorders in childhood. Philadelphia: WB Saunders, 1978.
- 13
- Emmanuele V, Kubota A, Garcia-Diaz B, et al. Fhl1 W122S causes loss of protein function and late-onset mild myopathy. Hum Mol Genet 2015;24(3):714-26. PMID 25274776
- 14
- Figarella-Branger D, Putzu GA, et al. Adult onset reducing body myopathy. Neuromuscul Disord 1999;9(8):580-6. PMID 10619716
- 15
- Fujii T, Hayashi S, Kawamura N, et al. A case of adult-onset reducing body myopathy presenting a novel clinical feature, asymmetrical involvement of the sternocleidomastoid and trapezius muscles. J Neurol Sci 2014;343(1-2):206-10. PMID 24928078
- 16
- Gayathri N, Yasha TC, Vani S, et al. Late onset glycogen storage disease type II with reducing body-like inclusions. Clin Neuropathol 2010;29(1):36-40. PMID 20040332
- 17
- Goebel HH. Congenital myopathies with inclusion bodies: a brief review. Neuromuscul Disord 1998;8(3-4):162-8. PMID 9631396
- 18
- Goebel HH. Congenital myopathies at their molecular dawning. Muscle Nerve 2003;27(5):527-48. PMID 12707973
- 19
- Goebel HH, Blaschek A. Protein aggregation in congenital myopathies. Semin Pediatr Neurol 2011;18(4):272-6. PMID 22172423
- 20
- Goebel HH, Halbig LE, Goldfarb L, et al. Reducing body myopathy with cytoplasmic bodies and rigid spine syndrome: a mixed congenital myopathy. Neuropediatrics 2001;32:196-205. PMID 11571700
- 21
- Hu Z, Zhu Y, Liu X, et al. FHL1-related clinical, muscle MRI and genetic features in six Chinese patients with reducing body myopathy. J Hum Genet 2019;64(9):919-26. PMID 31273321
- 22
- Hubner G, Pongratz D. Granular body myopathy (so-called reducing body myopathy). Pathologe 1982;3:111-3. PMID 7088899
- 23
- Ikezoe K, Nakagawa M, Osoegawa M, Kira J, Nonaka I. Ultrastructural detection of DNA fragmentation in myonuclei of fatal reducing body myopathy. Acta Neuropathol (Berl) 2004;107(5):439-42. PMID 14986028
- 24
- Janin A, Manel V, Millat G, et al. Reducing body myopathy as a new phenotype of Filamin C mutation. Neuromusc Dis 2017;27(Suppl 2) S120.
- 25
- Jokela M, Huovinen S, Palmio J, Saukkonen AM, Penttilä S, Udd B. Gluteus maximus hypertrophy: a diagnostic clue in four and a half LIM domain 1-mutated reducing body myopathy. Neuromuscul Disord 2017;27(10):962-3. PMID 28694073
- 26
- Kiyomoto BH, Murakami N, Kobayashi Y, et al. Fatal reducing body myopathy. Ultrastructural and immunohistochemistry observations. J Neurol Sci 1995;128:58-65. PMID 7722535
- 27
- Komagamine T, Kawai M, Kokubun N, et al. Selective muscle involvement in a family affected by a second LIM domain mutation of fhl1: An imaging study using computed tomography. J Neurol Sci 2012;318(1-2):163-7. PMID 22541254
- 28
- Kong Y, Shelton JM, Rothermel B, et al. Cardiac-specific LIM protein FHL2 modifies the hypertrophic response to beta-adrenergic stimulation. Circulation 2001;103(22):2731-8. PMID 11390345
- 29
- Leclerc A, Tome FM, Fardeau M. Ubiquitin and beta-amyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study. Neuromuscul Disord 1993;3:283-91. PMID 8268725
- 30
- Liewluck T, Hayashi YK, Ohsawa M, et al. Unfolded protein response and aggresome formation in hereditary reducing-body myopathy. Muscle Nerve 2007;35(3):322-6. PMID 17099882
- 31
- Lim KY, Kim HH, Sung JJ, Oh, Byung-Mo, Kim K, Park S. FHL1-mutated reducing body myopathy. Neuropathology 2020;40(2):185-90. PMID 31803391
- 32
- Maerkens A, Kley RA, Olive M, et al. Differential proteomic analysis of abnormal intramyoplasmic aggregates in desminopathy. J Proteomics 2013;90:14-27. PMID 23639843
- 33
- Malfatti E, Olive M, Taratuto AL, et al. Skeletal muscle biopsy analysis in reducing body myopathy and other FHL1-related disorders. J Neuropathol Exp Neurol 2013;72(9):833-45. PMID 23965743
- 34
- Mohassel P, Yun P, Syeda S, et al. A comprehensive study of skeletal muscle imaging in FHL1-related reducing body myopathy. Ann Clin Transl Neurol 2023;10(8):1442-55. PMID 37483011
- 35
- Navarro C, Fernandez JM, Gamez J, Teijera S, Cervera C. Reducing body myopathy with tubulofilamentous inclusions, rimmed vacuoles and accumulation of intermediate filaments. Clin Neuropathol 1994;13:160.
- 36
- Nomizu S, Person DA, Saito C, Lockett LJ. A unique case of reducing body myopathy. Muscle Nerve 1992;15:463-6. PMID 1314327
- 37
- Oh SJ, Meyers GJ, Wilson ER, Alexander CB. A benign form of reducing body myopathy. Muscle Nerve 1983;6:271-82. PMID 6306460
- 38
- Ohsawa M, Liewluck T, Ogata K, et al. Familial reducing body myopathy. Brain Dev 2007;29(2):112-6. PMID 16919903
- 39
- Park YE, Kim DS, Shin JH. Myofibrillar myopathy caused by a novel FHL1 mutation presenting a mild myopathy with ankle contracture. Clin Neurol Neurosurg 2019;180:48-51. PMID 30928807
- 40
- Reichmann H, Goebel HH, Schneider C, Toyka KV. Familial mixed congenital myopathy with rigid spine phenotype. Muscle Nerve 1997;20:411-7. PMID 9121497
- 41
- Sabatelli M, Bertini E, Ricci E, et al. Peripheral neuropathy with giant axons and cardiomyopathy associated with desmin-type intermediate filaments in skeletal muscle. J Neurol Sci 1992;109:1-10. PMID 1517757
- 42
- Sabatelli P, Castagnaro S, Tagliavini F, et al. Aggresome-autophagy involvement in a sarcopenic patient with rigid spine syndrome and a p.C150R mutation in FHL1 gene. Front Aging Neurosci 2014;19:215. PMID 25191266
- 43
- Satoyoshi E, Murakmi N, Takemitsu M, Nonaka I. In: Serratrice G, editor. Système Nerveux, Muscles et Maladies Systèmiques. Paris: Expansion Scientifique Françaises, 1993:83-92.
- 44
- Schessl J, Columbus A, Hu Y, et al. Familial reducing body myopathy with cytoplasmic bodies and rigid spine revisited: identification of a second LIM domain mutation in FHL1. Neuropediatrics 2010;41(1):43-6. PMID 20571991
- 45
- Schessl J, Feldkirchner S, Kubny C, Schoser B. Reducing body myopathy and other FHL1-related muscular disorders. Semin Pediatr Neurol 2011;18(4):257-263. PMID 22172421
- 46
- Schessl J, Taratuto AL, Sewry C, et al. Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1. Brain 2009;132(Pt 2):452-64. PMID 19181672
- 47
- Schessl J, Zou Y, McGrath MJ, et al. Proteomic identification of FHL1 as a protein mutated in human reducing body myopathy. J Clin Invest 2008;118(3):904-12. PMID 18274675
- 48
- Schreckenbach T, Henn W, Kress W, et al. Novel FHL1 mutation in a family with reducing body myopathy. Muscle Nerve 2013;47(1):127-34. PMID 23169582
- 49
- Shalaby S, Hayashi YK, Nonaka I, Noguchi S, Nishino I. Novel FHL1 mutations in fatal and benign reducing body myopathy. Neurology 2009;72(4):375-6. PMID 19171836
- 50
- Shinde A, Nakano S, Kusaka H, et al. Nucleolar characteristics of reducing bodies in reducing body myopathy. Acta Neuropathol (Berl) 2004;107(3):265-71. PMID 14735304
- 51
- Tanboon J, Sanmaneechai O, Charuvanij S, et al. Concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibody with reducing body myopathy: possible double trouble. Neuromuscul Disord 2019;29(7):543-8. PMID 31204143
- 52
- Tome FM, Fardeau M. Congenital myopathy with reducing bodies in muscle fibers. Acta Neuropathol (Berl) 1975;31:207-17. PMID 1138529
- 53
- Uruha A, Hayashi YK, Oya Y, et al. Necklace cytoplasmic bodies in hereditary myopathy with early respiratory failure. J Neurol Neurosurg Psychiatry 2015;86(5):483-9. PMID 25253871
- 54
- Wilding BR, McGrath MJ, Bonne G, Mitchell CA. FHL1 mutations that cause clinically distinct human myopathies form protein aggregates and impair myoblast differentiation. J Cell Sci 2014;127(Pt 10):2269-81. PMID 24634512
- 55
- Willis TA, Wood CL, Hudson J, et al. Muscle hypertrophy as the presenting sign in a patient with a complete FHL1 deletion. Clin Genet 2016;90:166-70. PMID 27409453
- 56
- Windpassinger C, Schoser B, Straub V, et al. An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. Am J Hum Genet 2008;82(1):88-99. PMID 18179888
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Ravi Uniyal MD DM
Dr. Uniyal of King George's Medical University has no relevant financial relationship to disclose.
See Profile
Editor
-
Ganeshwaran H Mochida MD
Dr. Mochida of Boston Children's Hospital and Harvard Medical School has no relevant financial relationships to disclose.
See Profile
Former Authors
- Joseph R Siebert PhD
- Enrico Bertini MD (original author) and Carlo Piantadosi MD
Patient Profile
- Age range of presentation
-
- 0 month to 44 years
- Sex preponderance
-
- female>male, 2>1
- Heredity
-
- heredity may be a factor
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-9
-
- Congenital hereditary muscular dystrophy: 359.0
- ICD-10
-
- Congenital myopathies: G71.2
- OMIM
-
- Reducing body myopathy 1A, severe infantile or early childhood onset: #300717
- Reducing body myopathy 1B, late childhood or adult onset: #300718
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuromuscular Disorders
Distal myopathies
Sep. 18, 2024
-
Epilepsy & Seizures
Epileptic lesions due to malformation of cortical development
Sep. 06, 2024
-
Peripheral Neuropathies
Amyotrophic lateral sclerosis
Sep. 04, 2024
-
Developmental Malformations
Agenesis of the corpus callosum
Aug. 23, 2024
-
Developmental Malformations
Epidermal nevus syndromes: neurologic phenotypes
Aug. 16, 2024
-
General Neurology
ALS-like disorders of the Western Pacific
Aug. 14, 2024
-
Developmental Malformations
Norrie disease
Aug. 11, 2024